MedPath
HSA Approval

ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

SIN17049P

ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

July 23, 2024

PFIZER PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPFIZER PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, FOR SOLUTION

INTRAMUSCULAR

Medical Information

J07BX05

Manufacturer Information

PFIZER PRIVATE LIMITED

Pfizer Manufacturing Belgium NV

Pfizer Manufacturing Belgium NV (Diluent)

Active Ingredients

(Powder) RSV subgroup A stabilized prefusion F protein

0.06 mg/vial

(powder) rsv subgroup a stabilized prefusion f protein

(Powder) RSV subgroup B stabilized prefusion F protein

0.06 mg/vial

(powder) rsv subgroup b stabilized prefusion f protein

Documents

Package Inserts

Abrysvo PI.pdf

Approved: July 23, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION - HSA Approval | MedPath